Skip to main content

Artemis to Provide Biovitrum with RNAi-modified Transgenic Mice

NEW YORK, July 7 (GenomeWeb News) - Artemis Pharmaceuticals will provide Biovitrum with RNAi-modified transgenic mice, the companies said today.

 

Under the agreement, Cologne, Germany-based Artemis will create shRNAi knock-down transgenic mice for Biovitrum of Stockholm, Sweden.

 

Biovitrum will use these mice, in which the expression of certain proteins will be down-regulated, in its pharmaceutical research programs.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.